Last reviewed · How we verify

NCT07072299

DEB-BACE for Primary Lung Cancer: A Retrospective, Single-Arm, Multicenter Study on Efficacy and Safety

Not yet recruiting Last updated 18 July 2025
What this trial tests

trial testing DEB-BACE in Lung Cancer Patients in 1,213 participants. Not yet recruiting.

Timeline
1 August 2025
Primary endpoint
1 August 2026
1 August 2026

Quick facts

Lead sponsorGang Wu, MD
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment1,213
Start date1 August 2025
Primary completion1 August 2026
Estimated completion1 August 2026

Drugs / interventions tested

Conditions studied

Sponsor

Gang Wu, MD

Who can join

18 and older, any sex, with Lung Cancer Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a retrospective, single-arm, multicenter clinical study designed to evaluate the efficacy and safety of DEB-BACE (Drug-Eluting Bead Bronchial Artery Chemoembolization) in the treatment of primary lung cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lung Cancer Patients

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07072299.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing